This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Mekinist
  • /
  • Study of Selective BRAF Kinase Inhibitor Dabrafeni...
Clinical trial

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell

Read time: 3 mins
Last updated:1st Jun 2011
Identifier: NCT01336634

Dabrafenib is a potent and selective inhibitor of BRAF kinase activity. This is a Phase II, non-randomized, open-label study to assess the efficacy, safety, and tolerability of dabrafenib administered as a single agent and in combination with trametinib in stage IV disease to subjects with BRAF mutant advanced non-small cell lung cancer. Subjects will receive dabrafenib 150 mg twice daily (BID) in monotherapy treatment and dabrafenib 150 mg bid and trametinib 2 mg once daily in combination therapy and continue on treatment until disease progression, death, or unacceptable adverse event.

Study Type: Interventional
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Study of the BRAF Inhibitor Dabrafenib as a Single Agent and in Combination With the MEK Inhibitor Trametinib in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer
Enrollment: 174
Study Start Date: June 2011
Estimated Study Completion Date: August 2016
Primary Completion Date: January 2016 (Final data collection date for primary outcome measure)

- Experimental:
Cohort A
- Experimental: Cohort B
- Experimental: Cohort C

Related journal:
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.

Category Value
Date last updated at source 2016-08-25
Study type(s) Interventional
Expected enrolment 174
Study start date 2011-06-01
Estimated primary completion date 2016-08-01

View full details